Flex Pharma Inc (NASDAQ:FLKS) – Analysts at Jefferies Group issued their FY2022 earnings per share estimates for shares of Flex Pharma in a report released on Tuesday. Jefferies Group analyst M. Andrews anticipates that the biotechnology company will earn ($0.08) per share for the year.
Several other analysts have also weighed in on the company. Ladenburg Thalmann Financial Services began coverage on Flex Pharma in a report on Thursday, January 25th. They set a “buy” rating and a $12.00 price objective on the stock. Cantor Fitzgerald reissued a “hold” rating and set a $10.00 price objective on shares of Flex Pharma in a report on Wednesday, January 17th. Roth Capital reissued a “buy” rating and set a $12.00 price objective on shares of Flex Pharma in a report on Wednesday, January 3rd. Finally, Zacks Investment Research lowered Flex Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Flex Pharma presently has a consensus rating of “Buy” and a consensus price target of $9.79.
A number of hedge funds have recently made changes to their positions in FLKS. Ameriprise Financial Inc. boosted its stake in Flex Pharma by 69.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 654,825 shares of the biotechnology company’s stock valued at $2,520,000 after buying an additional 268,505 shares in the last quarter. Sphera Funds Management LTD. acquired a new stake in Flex Pharma in the 3rd quarter valued at $2,341,000. Renaissance Technologies LLC boosted its stake in Flex Pharma by 67.1% in the 4th quarter. Renaissance Technologies LLC now owns 89,900 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 36,100 shares in the last quarter. Finally, Granite Point Capital Management L.P. boosted its stake in Flex Pharma by 80.8% in the 4th quarter. Granite Point Capital Management L.P. now owns 71,520 shares of the biotechnology company’s stock valued at $250,000 after buying an additional 31,961 shares in the last quarter. 27.26% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/14/jefferies-group-comments-on-flex-pharma-incs-fy2022-earnings-flks.html.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.